New trials show promise for tau-based therapy in the treatment of Alzheimer’s

Written by Roisin Conneely

LMTX®, an experimental tau aggregation inhibitor developed by TauRx Theraputics Ltd, has demonstrated promise for Alzheimer’s disease (AD) in its second Phase III trial. The results suggest that the drug may be effective in doses as low as 4mg, but only when used as a monotherapy. The study, published in the Journal of Alzheimer’s Diseases, explored drug effectiveness in 800 patients with mild AD, over a period of 18 months. Previously, researchers had reported results from initial Phase III trials, which examined dosages of 75mg and 125mg twice daily. The second stage of the current phase looked at dosages of...

To view this content, please register now for access

It's completely free